alexa Hydromorphone for Cancer Pain in HIV Patient: A Case Re
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Hydromorphone for Cancer Pain in HIV Patient: A Case Report

Daniel Madeira*

Department of Anesthesiology, Hospital and University Center of Coimbra, Praceta Prof. Mota Pinto 3000-075 Coimbra, Portugal

Corresponding Author:
Daniel Madeira
Department of Anesthesiology
Hospital and University Center of Coimbra
Praceta Prof. Mota Pinto 3000-075 Coimbra, Portugal
Tel: +351 969351006
E-mail: [email protected]

Received Date: December 13, 2016; Accepted Date: December 28, 2016; Published Date: January 05, 2017

Citation: Madeira D (2016) Hydromorphone for Cancer Pain in HIV Patient: A Case Report. J Antivir Antiretrovir 8:155-157. doi: 10.4172/jaa. 1000153

Copyright: © 2016 Madeira D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: Antiretroviral therapy has been implicated in significant interactions with a variety of drug classes used to treat comorbid conditions in patients with HIV.

Case report: Male, under oral antiretroviral therapy (emtricitabine 200 mg+tenofovir diproxil fumarate 300 mg id, atazanavir 300 mg id, ritonavir 100 mg id) diagnosed with end-stage pancreatic cancer. Treated orally for pain with paracetamol 1 g 3id, metamizol 575 mg 2id and tramadol 100 mg 3id with poor analgesic control, a Numerical Pain Rating Scale=8. All the analgesic drugs prescribed were discontinued and started hydromorphone extended-release formulation 8 mg id per os with a reduction in the pain to Numerical Pain Rating Scale=0.

Discussion: There is a lack of precise scientific evidence to infer safety conclusions from the concomitant administration of hydromorphone and antiretroviral therapy. Limited existing studies suggest that there is no clinically significant interaction between either emtricitabine or tenofovir with hydromorphone. Regarding atazanavir and ritonavir, coadministration with hydromorphone has not been studied, they both induce glucuronidation and could decrease the opioid analgesic effect.

Conclusions: Since there is a lack of precise scientific evidence to infer safety conclusions from the concomitant administration of these drugs, more studies need to be performed.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords